Earnings To Watch: Repligen (RGEN) Reports Q4 Results Tomorrow

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results tomorrow morning. Here’s what you need to know.

Repligen beat analysts’ revenue expectations by 0.9% last quarter, reporting revenues of $154.9 million, up 9.7% year on year. It was a very strong quarter for the company, with an impressive beat of analysts’ EPS estimates and a solid beat of analysts’ organic revenue estimates.

Is Repligen a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Repligen’s revenue to be flat year on year at $167.7 million, improving from the 10.8% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.41 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Repligen has missed Wall Street’s revenue estimates four times over the last two years.

Looking at Repligen’s peers in the drug development inputs & services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Azenta delivered year-on-year revenue growth of 4.1%, beating analysts’ expectations by 1.1%, and Charles River Laboratories reported a revenue decline of 1.1%, topping estimates by 2.3%. Azenta traded up 4% following the results.

Read our full analysis of Azenta’s results here and Charles River Laboratories’s results here.

Investors in the drug development inputs & services segment have had fairly steady hands going into earnings, with share prices down 2% on average over the last month. Repligen is down 13.5% during the same time and is heading into earnings with an average analyst price target of $191 (compared to the current share price of $145.18).

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.